Fearing sanction, Thais may pay for drugs

Thailand may be running scared. Remember, the new health minister promised last week to review the country's compulsory licenses--which essentially break patent rules so that cheap meds can be had during health emergencies. Now, Chaiya Sasomsa says he'd rather buy the expensive cancer drugs his predecessor co-opted, because the alternative may be trade sanctions.

The World Trade Organization allows compulsory licenses if public health demands it. But apparently, Thailand officials are worried that the policy could undermine relations with trading partners. The U.S. Trade Rep, for one, put Thailand on its Priority Watch list because of the patent-breaking.

- read the item at Pharmalot

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.